Skip to main content
PMC home page
AAPS PharmSci logoLink to AAPS PharmSci
. 2002 Jul 11;4(3):12–21. doi: 10.1208/ps040313

Aerosolization of lipoplexes using AERx® pulmonary delivery system

Deepa Deshpande 1,✉, James Blanchard 1, Sudarshan Srinivasan 1, Dallas Fairbanks 2, Jun Fujimoto 2, Teiji Sawa 2, Jeanine Wiener-Kronish 2, Hans Schreier 3, Igor Gonda 1
PMCID: PMC2751352  PMID: 12423062

Abstract

The lung represents an attractive target for delivering gene therapy to achieve local and potentially systemic delivery of gene products. The objective of this study was to evaluate the feasibility of the AERx Pulmonary Delivery System for delivering nonviral gene therapy formulations to the lung. We found that “naked” DNA undergoes degradation following aerosolization through the AERx nozzle system. However, DNA formulated with a molar excess of cationic lipids (lipoplexes) showed no loss of integrity. In addition, the lipoplexes showed no significant change in particle size, zeta (ζ) potential, or degree of complexation following extrusion. The data suggest that complexation with cationic lipids had a protective effect on the formulation following extrusion. In addition, there was no significant change in the potency of the formulation as determined by a transfection study in A-549 cells in culture. We also found that DNA formulations prepared in lactose were aerosolized poorly. Significant improvements in aerosolization efficiency were seen when electrolytes such as NaCl were added to the formulation. In conclusion, the data suggest that delivery of lipoplexes using the AERx Pulmonary Delivery System may be a viable approach for pulmonary gene therapy.

KeyWords: Aerosol, Gene therapy, Formulation, Plasmid, Lipoplex, Fluorescence assay

References

  • 1.Cavazzana-Calvo M, Hacein-Bay S, Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. doi: 10.1126/science.288.5466.669. [DOI] [PubMed] [Google Scholar]
  • 2.Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24(3):257–261. doi: 10.1038/73464. [DOI] [PubMed] [Google Scholar]
  • 3.Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;102(9):965–974. doi: 10.1161/01.cir.102.9.965. [DOI] [PubMed] [Google Scholar]
  • 4.Anderson WF. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999;10:2037–2088. doi: 10.1089/10430349950017400. [DOI] [PubMed] [Google Scholar]
  • 5.Pillai R, Petrak K, Blezinger P, et al. Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharm Res. 1998;15(11):1743–1747. doi: 10.1023/A:1011964813817. [DOI] [PubMed] [Google Scholar]
  • 6.Stern M, Sorgi F, Hughes C, et al. The effects of jet nebulization on cationic liposome-mediated gene transfer in vitro. Gene Ther. 1998;5:583–593. doi: 10.1038/sj.gt.3300629. [DOI] [PubMed] [Google Scholar]
  • 7.Schreier H, Gagne L, Conary JT, Laurian G. Simulated lung transfection by nebulization of liposome cDNA complexes using a cascade impactor seeded with 2-CFSME cells. J Aerosol Med. 1998;11(1):1–13. doi: 10.1089/jam.1998.11.1. [DOI] [PubMed] [Google Scholar]
  • 8.Schwarz LA, Johnson J, Black M, Cheng S, Hogan M, Waldrep JC. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther. 1996;7:731–741. doi: 10.1089/hum.1996.7.6-731. [DOI] [PubMed] [Google Scholar]
  • 9.Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone G. RhDNase 1 aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1662–1668. doi: 10.1164/ajrccm.156.5.9604093. [DOI] [PubMed] [Google Scholar]
  • 10.Schuster JA, Rubsamen RM, Lloyd P, Lloyd J. The AERx Aerosol Delivery System. Pharm Res. 1996;14:354–357. doi: 10.1023/A:1012058323754. [DOI] [PubMed] [Google Scholar]
  • 11.Mudumba S, Khossravi M, Yim D, et al. Delivery of rhDNase by the AERx Pulmonary Delivery System. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Respiratory Drug Delivery VII. Buffalo Grove, IL: Inter Pharm Press; 2000. pp. 329–332. [Google Scholar]
  • 12.Farr S, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx System: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther. 2000;2:185–197. doi: 10.1089/15209150050025131. [DOI] [PubMed] [Google Scholar]
  • 13.Cipolla D, Boyd B, Evans R, et al. Bolus administration of INS365 studying the feasibility of delivering high cose drugs using the AERx Pulmonary Delivery System. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Respiratory Drug Delivery VII. Buffalo Grove, IL: InterPharm Press; 2000. pp. 83–90. [Google Scholar]
  • 14.Lui K, Dayton F, Shi S, Farr SJ, Gonda I, Development of fentanyl citrate AERx system for pulmonary delivery. Paper presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition: November 1999; New Orleans, LA.
  • 15.Sorgi F, Gagne L, Sharif S, et al. Aerosol gene delivery using the AERx Delivery System. Proceed Intern Symp Control Rel Bioact Mat. 1998;25:184–185. [Google Scholar]
  • 16.Schuster J, Farr S, Cipolla D, et al. Design and performance validation of a highly efficient and reproducible compact aerosol delivery system: AERx®. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Respiratory Drug Delivery VI. Buffalo Grove, IL: InterPharm Press; 1998. pp. 83–90. [Google Scholar]
  • 17.Chan H, Daviskas E, Eberl S, Robinson M, Bautovich G, Young I. Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system (AERx) in healthy subjects. Eur J Nucl Med. 1999;26(4):320–327. doi: 10.1007/s002590050393. [DOI] [PubMed] [Google Scholar]
  • 18.Clauson PG, Balent B, Brunner GA, et al. PK-PD of four different doses of pulmonary insulin delivered with AERx Diabetes Management System. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Respiratory Drug Delivery VII. Buffalo Grove, IL: InterPharm Press; 2000. pp. 83–90. [Google Scholar]
  • 19.Farr SJ, Schuster JA, Lloyd P, Lloyd LJ, Okikawa JK, Rubsamen R. AERx: development of a novel liquid aerosol delivery system: concept to clinic. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V. Buffalo Grove, IL: InterPharm Press; 1996. pp. 175–184. [Google Scholar]
  • 20.Densmore CL, Orson FM, Xu B, et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther. 2000;1(2):180–188. doi: 10.1006/mthe.1999.0021. [DOI] [PubMed] [Google Scholar]
  • 21.Chander R, Schreier H. Artificial viral envelopes containing recombinant HIV gp160. Life Sci. 1992;50:481–489. doi: 10.1016/0024-3205(92)90387-5. [DOI] [PubMed] [Google Scholar]
  • 22.McDonald RJ, Liggitt HD, Roche L, et al. Aerosol delivery of lipid: DNA complexes to lungs of rhesus monkeys. Pharm Res. 1998;15(5):671–679. doi: 10.1023/A:1011902532163. [DOI] [PubMed] [Google Scholar]
  • 23.Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone G. RhDNase 1 aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1662–1668. doi: 10.1164/ajrccm.156.5.9604093. [DOI] [PubMed] [Google Scholar]
  • 24.Jones PD, Mortiz V, Pierce RJ. Microbial contamination of domiciliary nebuliser therapy equipment. Aust N Z J Med. 1985;15:585–589. [PubMed] [Google Scholar]
  • 25.Kuhn RJ, Lubin AH, Jones PR, Nahata MC. Bacterial contamination of aerosol solutions used to treat cystic fibrosis. Am J Hosp Pharm. 1982;39(2):308–309. [PubMed] [Google Scholar]
  • 26.Ward ME, Woodhouse A, Mather LE, et al. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmakokinet Ther. 1997;62(6):596–609. doi: 10.1016/S0009-9236(97)90079-5. [DOI] [PubMed] [Google Scholar]
  • 27.Boyle F, Mather LE, Lam J, et al. Inhaled fentanyl via the AERx system for the treatment of breakthrough cancer pain. Poster presented at: 19th Annual Scientific Meeting. American Pain Society; November 3, 2000; Atlanta, GA.
  • 28.Gonda I, Schuster J, Rubsamen R, Lloyd P, Cipolla D, Farr S. Inhalation delivery systems with compliance and disease management capabilities. J Control Release. 1998;53:269–274. doi: 10.1016/S0168-3659(97)00260-5. [DOI] [PubMed] [Google Scholar]
  • 29.Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: Gamma camera analysis of regional deposition and perfusion. J Aerosol Med. 2001;14(2):185–195. doi: 10.1089/08942680152484117. [DOI] [PubMed] [Google Scholar]
  • 30.Cao A, Briane D, Coudert R, et al. Delivery and pathway in MCF7 cells of DNA vectorized by cationic liposomes derived from cholesterol. Antisense Nucl Acid Drug Deliv. 2000;10:369–380. doi: 10.1089/oli.1.2000.10.369. [DOI] [PubMed] [Google Scholar]
  • 31.Rosell J, Schuster J, Gonda I, Liu K. Electrostatic charge in AERx aerosols. Drug Delivery to the Lungs. 2000;XI:64–67. [Google Scholar]
  • 32.Rosell J, Schuster J, Liu K, et al. Suppression of electrostatic changing of AERx aerosols. J Aerosol Med. 2001;14(3):405–405. [Google Scholar]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES